Patent Peril | Explore Pacira's battle against generic competition as legal challenges threaten its flagship product Exparel, potentially eroding market share and revenues |
NOPAIN, Big Gain? | Delve into Pacira's NOPAIN initiative and new partnerships, offering hope for growth amid challenges in the non-opioid pain management market |
Outpatient Opportunity | Learn how recent CMS rule changes could boost Pacira's Exparel and iovera adoption in outpatient settings, expanding market reach |
Financial Fortitude | Analysts set price targets ranging from $14 to $37, with Pacira's strong margins and cash flow suggesting resilience despite market headwinds |
Metrics to compare | PCRX | Peers Peers - average of corresponding metrics from companies closely matching PCRX: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipPCRXPeersSector |
|---|---|---|---|---|
P/E Ratio | 38.8x | 0.0x | −0.2x | |
PEG Ratio | 0.41 | 0.00 | 0.00 | |
Price/Book | 2.1x | 0.0x | 2.6x | |
Price / LTM Sales | 2.0x | 0.0x | 2.7x | |
Upside (Analyst Target) | - | 0.0% | 72.2% | |
Fair Value Upside | Unlock | 0.0% | 12.4% | Unlock |